Breathless encounters: Analyzing anaphylaxis at the crossroads of COVID-19 vaccination.

Autor:	Paul, Pradipta, Janjua, Emmad, AlSubaie, Mai, Ramadorai, Vinutha, Mushannen, Beshr, Vattoth, Ahamed Lazim, Khan, Wafa, Bshesh, Khalifa, Nauman, Areej, Mohammed, Ibrahim, Bouhali, Imane, Khalid, Mohammed, Zakaria, Dalia
Předmět:	COVID-19 vaccines ANAPHYLAXIS VACCINE safety MEDICAL personnel
Zdroj:	Qatar Medical Journal; 2024, Vol. 2024 Issue 2, p1-2, 2p
Abstrakt:	This article, published in the Qatar Medical Journal, analyzes the occurrence of anaphylaxis following COVID-19 vaccination. The study conducted a systematic review of available data, including 41 studies from 14 countries. Among the reported cases of anaphylaxis, Pfizer accounted for the majority, followed by AstraZeneca and Moderna. Most cases involved females with a history of allergies, and the majority occurred within 30 minutes of the first dose. The primary treatment for anaphylaxis was epinephrine. The article concludes with recommendations for healthcare professionals to mitigate risks and ensure patient safety during the vaccination process. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.